Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04301778 · ClinicalTrials.gov registry record · Phase 2
Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
A Phase 2 study of Unresectable Intrahepatic Cholangiocarcinoma, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- Completed
- Registry status
- Phase 2
- Development phase
- 5
- Enrollment target
- 1
- Study location
NCT04301778 is a Phase 2 study of Unresectable Intrahepatic Cholangiocarcinoma that has completed, run by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. The registered enrollment target is 5 participants, below the 35-participant average among 3 other Unresectable Intrahepatic Cholangiocarcinoma trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04301778, a Phase 2 study of Unresectable Intrahepatic Cholangiocarcinoma, has completed, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 5 participants
- Enrollment target
- 1
- Study location
Study Summary
The purposed of this research is to study the safety and clinical activity of the combination of durvalumab and a CSF-1R inhibitor (SNDX-6352) in people with Intrahepatic Cholangiocarcinoma.
Conditions Studied
Interventions
- DRUG Durvalumab
- DRUG SNDX-6352
Study Locations (1)
Maryland
- Sidney Kimmel Comprehensive Cancer Center - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2021-08-24 |
| Est. Completion | 2024-02-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04301778
The ClinicalTrials.gov registry entry for NCT04301778 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 35-participant average among 3 other Unresectable Intrahepatic Cholangiocarcinoma trials with a reported enrollment target (86% lower). The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Unresectable Intrahepatic Cholangiocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Durvalumab is the first listed.
NCT04301778 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT04301778 about?
NCT04301778 is a clinical study titled "Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma". The purposed of this research is to study the safety and clinical activity of the combination of durvalumab and a CSF-1R inhibitor (SNDX-6352) in people with Intrahepatic Cholangiocarcinoma.
What is the current status of trial NCT04301778?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 5 participants. The study started on 2021-08-24. Estimated completion is 2024-02-06.
What conditions does trial NCT04301778 study?
This clinical trial studies the following conditions: Unresectable Intrahepatic Cholangiocarcinoma.
What interventions are being tested in trial NCT04301778?
The interventions under investigation include: Durvalumab (DRUG), SNDX-6352 (DRUG).
Who is sponsoring clinical trial NCT04301778?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, which has 523 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04301778 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unresectable Intrahepatic Cholangiocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma
ACTIVE NOT RECRUITING · Phase 2
-
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
RECRUITING · Phase 1
-
Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.